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Duration of post-stent clopidogrel treatment: a prescribing 
audit in primary care
Katherine Lucy Maskell 
Abstract 
Background Coronary artery disease is the most common cause of mortality worldwide; in 2015, it was responsible 
for 69 163 deaths in the UK. When clinically appropriate, the National Institute for Health and Care Excellence 
recommends percutaneous coronary intervention (PCI), often involving stent insertion. To reduce the risk of post-
stent thrombosis, dual antiplatelet therapy for up to 12 months after PCI is recommended, unless otherwise speciﬁ ed. 
Prolonged therapy can increase risk of bleeding and is rarely recommended. This audit aimed to determine whether 
patients in one general practice received the appropriate duration of clopidogrel treatment.
Methods In January, 2016, an electronic notes audit was undertaken in an 8000-patient general practice in Brighton, 
UK, to identify the number of patients undergoing PCI, and to determine whether these patients received up 
to 12 months of dual antiplatelet therapy post intervention. Patients were identiﬁ ed with the codes “insertion coronary 
artery stent” and “coronary angioplasty”, who also had a clopidogrel prescription issued in the past 10 years. Reasons 
for undertreatment and overtreatment were assessed. 
Findings 32 patients (0·004%) had PCI and subsequent clopidogrel treatment. 22 of them (69%, 95% CI 53–85) received 
up to 12 months’ clopidogrel treatment, and eight (25%, 10–40) received less than 10 months’, of whom only one had 
a valid reason documented. Ten patients (31%, 15–47) exceeded the recommended treatment, of whom only four 
had a valid reason documented.
Interpretation This audit identiﬁ ed that duration of clopidogrel treatment was inappropriate in around two-ﬁ fths 
of patients. This ﬁ nding demonstrates a speciﬁ c example of a wider issue of concordance with recommendations 
after initiation of an appropriate medication, and the lack of a system to stop prescriptions after a particular period 
of time. Limitations include the small sample size, the potential for recommendations to have changed during the 
retrospective period, and the possibility of miscoding of patients. Patients receiving antiplatelet therapy after PCI 
should have the appropriate treatment duration documented in their notes and included on the prescription, with 
further prescriptions not being issued until the end-date has been reviewed. This study highlights the importance 
of an eﬃ  cient health-care primary–secondary–tertiary interface.
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